A Novavax spokesperson said they had data showing their vaccine candidate for the fall aimed at JN.1 has "good cross-reactivity" for KP.2. While Novavax's vaccine takes longer to make than the mRNA shots from Pfizer and Moderna, the spokesperson said FDA's delay to the meeting "will no...